Compare
ADMA Biologics vs Gilead Sciences (ADMA vs GILD)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year ADMA Biologics (ADMA) returned -17.2% and Gilead Sciences (GILD) +36.1%; so far this year the figures are -30.2% and +36.0%.
Gilead Sciences is the larger company by market value, about 73.4 times the size of ADMA Biologics.
Revenue grew +6.3% at ADMA and +6.5% at GILD over the last year.
ADMA pays no dividend. GILD yields 1.95%.
Data as of the latest close. Not investment advice.
Relative performance
| ADMA | GILD | |
|---|---|---|
| Price | $12.73 | $166.89 |
| 1-day | -3.63% | -0.41% |
| YTD | -30.21% | +35.97% |
| 1 year | -17.18% | +36.15% |
| 3 years | +261.65% | +108.12% |
| Market cap | $2.8B | $207.0B |
| P/E | 16.5 | — |
| P/S | 5.44 | 6.68 |
| P/B | 6.44 | 15.87 |
| Revenue growth | +6.30% | +6.50% |
| EPS growth | -10.50% | -149.00% |
| Gross margin % | 68.5 | 79.9 |
| Net margin % | 35.1 | -12.5 |
| ROE % | 41.6 | -29.6 |
| Debt / equity | 0.45 | 2.01 |
| FCF yield % | 4.7 | 6.7 |
| Dividend yield % | — | 1.95 |
| Beta | 0.07 | 0.37 |
| RSI (14) | 65.8 | 60.2 |
| Technical rating |